1. Home
  2. KRKR vs LABT Comparison

KRKR vs LABT Comparison

Compare KRKR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 36Kr Holdings Inc.

KRKR

36Kr Holdings Inc.

N/A

Current Price

$3.00

Market Cap

5.6M

ML Signal

N/A

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.27

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRKR
LABT
Founded
2010
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.6M
IPO Year
2019
2026

Fundamental Metrics

Financial Performance
Metric
KRKR
LABT
Price
$3.00
$2.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.0K
2.0M
Earning Date
03-17-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$1.66
52 Week High
$21.36
$6.85

Technical Indicators

Market Signals
Indicator
KRKR
LABT
Relative Strength Index (RSI) 57.27 42.88
Support Level $2.84 $2.10
Resistance Level $3.25 $2.50
Average True Range (ATR) 0.22 0.26
MACD 0.04 0.05
Stochastic Oscillator 71.21 57.14

Price Performance

Historical Comparison
KRKR
LABT

About KRKR 36Kr Holdings Inc.

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in the PRC.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: